Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Leuprolide acetate is a prescription gonadotropin-releasing hormone agonist. This page focuses on the current short-acting leuprolide acetate injection containing 1 mg per 0.2 mL. It is indicated for palliative treatment of advanced prostate cancer and is distinct from long-acting depot leuprolide products with different indications and schedules.
read more about leuprolide ...Leuprolide initially stimulates pituitary gonadotropin release, which temporarily raises testosterone. With continuous administration, pituitary gonadotropin secretion becomes suppressed and testosterone concentrations fall to castrate levels, commonly within two to four weeks.
Current short-acting leuprolide acetate injection is used for palliative treatment of advanced prostate cancer. Patients with metastatic vertebral lesions or urinary tract obstruction are observed closely during the first weeks due to the risk of worsening symptoms.
The recommended dose is 1 mg, equal to 0.2 mL, by subcutaneous injection once daily. Injection sites are varied periodically. Testosterone and prostate-specific antigen concentrations are monitored during treatment.
Leuprolide can cause an initial tumor flare with increased bone pain and can contribute to ureteral obstruction or spinal cord compression. Other serious concerns include severe cutaneous adverse reactions, hyperglycemia, diabetes, myocardial infarction, sudden cardiac death, stroke, QT prolongation, hypersensitivity, and fetal harm.
It is indicated for palliative treatment of advanced prostate cancer.
The recommended dose is 1 mg by subcutaneous injection once daily.
Leuprolide initially raises testosterone before sustained treatment suppresses hormone production, which can temporarily worsen prostate cancer symptoms.
No. Long-acting depot products have different dosing schedules and can have different labeled indications.
DailyMed - LEUPROLIDE ACETATE injection. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d6bd26bd-b8d8-4c5a-bc5c-7b8a1efaa584. Date Accessed October 12, 2026.
Leuprolide. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK548676/. Date Accessed October 12, 2026.
Leuprolide Acetate. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/drugs/leuprolideacetate. Date Accessed October 12, 2026.
Leuprolide Acetate. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Leuprolide-Acetate. Date Accessed October 12, 2026.
Leuprolide Injection. MedlinePlus. https://www.medlineplus.gov/druginfo/meds/a685040.html. Date Accessed October 12, 2026.